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A 72-year-old female underwent gastric bypass with 
concomitant cholecystectomy by laparoscopy in 2004 
for morbid obesity. Fifteen years later, the patient 
developed progressive dysphagia for solid food 
and lost 20 kg in the past 8 months with general 
asthenia and protein–calorie malnutrition. After 
multiple examinations (computed tomography scan, 
esophagogastroduodenoscopy, and positron emission 
tomography–computed tomography), the patient 
was found to have stage IV gastric adenocarcinoma 
(isolated cells, HER-2 negative, and microsatellite stable) 
of  the pyloric and prepyloric region of  the gastric 
remnant with peritoneal carcinosis. The tumor was 
extrinsically compressing the jejunum (alimentary limb) 
right after the gastrojejunal anastomosis causing an 
obstruction. After multidisciplinary tumor board 
discussion, the expected survival was estimated to be 
around 6 months and palliative chemotherapy with 
fluorouracil, leucovorin, oxaliplatin, and docetaxel 
was initiated. As the patient was still symptomatic 
and a new dilatation of  the bile ducts was noted 
(alkaline phosphatase: 170 U/L, gamma-glutamyl 
transpeptidase: 160 U/L, and transaminases and 
bilirubin: normal), it was decided to realize an 
EUS-directed gastrogastric anastomosis using a 
metallic Hot AXIOS™ stent [20 mm × 10 mm, 
Boston Scientific, Figure 1a and b]. This strategy 
was adopted to be able to reach the remnant gastric 
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Figure 1. (a) Fluoroscopic image showing the stent between the 
gastric pouch and the gastric remnant (gastrogastrostomy) and 
the feeding tube passing through the gastrojejunal anastomosis. 
(b) Endoscopic view of the stent between the gastric pouch and the 
gastric remnant (gastrogastrostomy)
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cancer in order to put a gastroduodenal uncovered 
stent (TaeWoong Medical, 22 mm of  diameter and 
12 cm of  length) and dilate the tumoral stenosis 
[Video 1 and Figure 2a-c], to recreate the physiological 
digestive path to improve her caloric intake, and to 
have potential access to the biliary tree if  needed. 
A jejunal self-expandable metallic stent in the alimentary 
limb was not considered due to the risk of  stent 
migration and impaction. Moreover, surgical and 
percutaneous procedures were not considered because 
Roux-en-Y gastric bypass precludes direct endoscopic 
evaluations of  the excluded stomach, which renders 
detection of  a tumor of  the gastric remnant 
challenging.[1,2] EUS-directed gastrogastric anastomosis 
using a metallic stent after Roux-en-Y gastric bypass 
enables to regain access to the remnant excluded 
stomach and to reach the pancreatobiliary limb.[3,4] This 
recently described EUS technique should be considered 
a promising technique in patients with gastric bypass 
presenting with choledocolithiasis or cancer of  the 
gastric remnant.
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Figure 2. (a) Deployment of the gastroduodenal stent visualized under 
fluoroscopy. (b) Endoscopic view of the stent in the gastroduodenal 
stenosis. (c) Final fluoroscopic image with the metallic stent 
gastrogastrostomy, the gastroduodenal stent, and the feeding tube 
passing through the gastrojejunal anastomosis
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of  the presence of  peritoneal carcinosis and ascites in 
important quantity. She was able to leave the hospital 
3 weeks after the last endoscopic procedure. The 
patient unfortunately died a couple of  weeks later due 
to rapid disease progression.
